NIS for Patients Using Symbicort Turbuhaler for Maintenance and Reliever Therapy in a Single Inhaler - Full Text View

NIS for Patients Using Symbicort Turbuhaler for Maintenance and Reliever Therapy in a Single Inhaler (SYMCO)

This study has been completed.

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00557297

Purpose

The aim of this non-interventional study is to ensure that patients in routine clinical practice follow given treatment instructions and to evaluate the number of reliever inhalations as well as the number of patient/days with more than 8/12 total inhalations at any day. If the number of reliever inhalations and thus the received inhaled glucocorticosteroid dose is not excessive, the safety conclusions from the clinical studies can be extrapolated to real life for better acceptance of SMART (Symbicort Maintenance and Reliever Therapy).

Condition
Asthma

MedlinePlus related topics: Asthma

Drug Information available for: Symbicort

U.S. FDA Resources

Study Type:	Observational
Study Design:	Cross-Sectional
Official Title:	NIS for Patients Using Symbicort Turbuhaler for Maintenance and Reliever Therapy in a Single Inhaler

Further study details as provided by AstraZeneca:

Biospecimen Retention: Samples With DNA

Biospecimen Description:

Estimated Enrollment:	250
Study Start Date:	October 2007
Study Completion Date:	September 2008

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Persistent asthma
Prior Symbicort Turbuhaler maintenance and reliever therapy in a single inhaler

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00557297

Locations

Latvia
Research Site
Aozkraukle, Latvia
Research Site
Aluksne, Latvia
Research Site
Balvi, Latvia
Research Site
Cesis, Latvia
Research Site
Gulbene, Latvia
Research Site
Jekabpils, Latvia
Research Site
Jumprava, Latvia
Research Site
Kekava, Latvia
Research Site
Kraslava, Latvia
Research Site
Kuldiga, Latvia
Research Site
Limbazi, Latvia
Research Site
Ventspils, Latvia
Research Site
Livani, Latvia
Research Site
Madona, Latvia
Research Site
Ogre, Latvia
Research Site
Preili, Latvia
Research Site
Rezekne, Latvia
Research Site
Salacgriva, Latvia
Research Site
Saldus, Latvia
Research Site
Talsi, Latvia
Research Site
Valniera, Latvia
Research Site
Liepaja, Latvia

Sponsors and Collaborators

AstraZeneca

More Information

Study ID Numbers:	D5890L00031
Study First Received:	November 9, 2007
Last Updated:	September 24, 2008
ClinicalTrials.gov Identifier:	NCT00557297
Health Authority:	Latvia: State Agency of Medicines

Keywords provided by AstraZeneca:

asthma
SMART
inhaled
glucocorticosteroid

reliever
maintenance
single inhaler

Study placed in the following topic categories:

Hypersensitivity
Lung Diseases, Obstructive
Symbicort
Respiratory Tract Diseases

Lung Diseases
Hypersensitivity, Immediate
Asthma
Respiratory Hypersensitivity

Additional relevant MeSH terms:

Respiratory System Agents
Immune System Diseases
Bronchial Diseases

Therapeutic Uses
Anti-Asthmatic Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 15, 2009